Data as of Dec 11
| -8.39 / -7.07%|
The 14 analysts offering 12-month price forecasts for Pharmacyclics Inc have a median target of 143.50, with a high estimate of 170.00 and a low estimate of 104.00. The median estimate represents a +30.10% increase from the last price of 110.30.
The current consensus among 17 polled investment analysts is to Buy stock in Pharmacyclics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.